Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × Lung Neoplasms × brigatinib × Clear all

Status

Active not recruiting 4 Terminated 2 Completed 2 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Large Cell 1 Carcinoma 1 Adenocarcinoma 1

Interventions

taletrectinib 1 dabrafenib 1 capmatinib 1 brigatinib 1 Suspensions 1 Powders 1 Paclitaxel 1 BID protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02784158 2018-02-06

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Takeda

No longer available

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡